Two-thirds of Myanmar HIV patients untreated: MSF

February 22, 2012

International funding cuts threaten to deepen an HIV crisis in Myanmar, where tens of thousands of people are denied lifesaving treatment, an aid agency said Wednesday.

Medecins Sans Frontieres (Doctors Without Borders) said only a third of the 120,000 people in need of in Myanmar were receiving the therapy, with up to 20,000 people dying each year due to a lack of treatment.

MSF Myanmar head Peter Paul de Groote said there was already an "unacceptable" gap in treatment and warned the situation would worsen without further funding.

"In Myanmar, we have a situation where there is willingness and the capacity to scale up, so if more money would flow into the country we think, combined with better access, we could close that gap," he told reporters in Bangkok.

The Paris-based aid agency said the cancellation of an entire round of support by the Global Fund to Fight , and Malaria has left it with limited funds to treat a further 40,000 people.

The Global Fund, which receives donations from governments and the private sector, is a major financier of programmes to treat its three target illnesses worldwide.

"It is an unacceptable situation. You have to tell someone: 'You are not sick enough, so please come back later, maybe then you'll be sick enough and we can give you the treatment'," said de Groote.

Myanmar's former junta prioritised , leaving healthcare in tatters.

While a new quasi-civilian regime which took power last year is likely to boost funding, MSF said it would be years before the is fully functioning.

Recent political reforms have sparked hopes of an increase in aid to the country -- the least developed in the region and one of the lowest recipients of development aid in the world.

MSF urged the international community to make tackling HIV and tuberculosis (TB) a top donor priority for the nation, which would need to spend around $560 per every year on treatment.

TB is the most common cause of death for HIV patients in the world.

The MSF Lives in the Balance report said Myanmar has a high prevalence of multidrug-resistant tuberculosis (MDR-TB), which is more difficult and expensive to treat.

Of an estimated 9,300 people newly infected with this disease each year, only around 300 have been receiving treatment.

"Without increased availability of treatment, and TB will continue to spread unchecked in many areas. The time to treat is now," said MSF Doctor Khin Nyein Chan.

Related Stories

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.